KRAS and pancreatitis: As supported by substantial evidence in many experimental models, when it manifests in the context of pancreatitis, Mutations in KRAS, a common oncogenic driver of pancreatic cancer, lead to accelerated tumor development, and induce the appearance of neoplastic precursor lesions [75, 76].